BrainStorm Cell Therapeutics announced positive data from a Phase II safety and efficacy study of NurOwn in progressive multiple sclerosis on Oct. 14.

BrainStorm Cell Therapeutics, one of the leading developers of adult stem cell therapies that mainly focuses on adult neurodegenerative diseases, reported that the company’s 28-week-long Phase II clinical trial for progressive multiple sclerosis (MS) came to a close.

MediciNova received positive Optical Coherence Tomography (OCT) results from the company’s SPRINT-MS Phase IIb trial of MN-166 (ibudilast) in multiple sclerosis subjects.

France-based MedDay Pharmaceuticals announced the company’s MED1003 failed to meet the primary and secondary endpoints in the second pivotal Phase III trial for progressive multiple sclerosis (MS).